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Modeling anorexia nervosa: transcriptional insights from
human iPSC-derived neurons
PD Negraes1,6, FR Cugola1,6, RH Herai1,2, CA Trujillo1, AS Cristino3, T Chailangkarn1,4, AR Muotri1 and V Duvvuri5
Anorexia nervosa (AN) is a complex and multifactorial disorder occurring predominantly in women. Despite having the highest
mortality among psychiatric conditions, it still lacks robust and effective treatment. Disorders such as AN are most likely syndromes
with multiple genetic contributions, however, genome-wide studies have been underpowered to reveal associations with this
uncommon illness. Here, we generated induced pluripotent stem cells (iPSCs) from adolescent females with AN and unaffected
controls. These iPSCs were differentiated into neural cultures and subjected to extensive transcriptome analysis. Within a small
cohort of patients who presented for treatment, we identified a novel gene that appears to contribute to AN pathophysiology,
TACR1 (tachykinin 1 receptor). The participation of tachykinins in a variety of biological processes and their interactions with other
neurotransmitters suggest novel mechanisms for how a disrupted tachykinin system might contribute to AN symptoms. Although
TACR1 has been associated with psychiatric conditions, especially anxiety disorders, we believe this report is its first association with
AN. Moreover, our human iPSC approach is a proof-of-concept that AN can be modeled in vitro with a full human genetic
complement, and represents a new tool for understanding the elusive molecular and cellular mechanisms underlying the disease.
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INTRODUCTION
Anorexia nervosa (AN) is a multifactorial neurodevelopmental
disorder of unknown etiology affecting around 1% of the
population.1 With a stereotypic post-pubertal onset, this complex
neuropsychiatric condition is primarily seen in female adolescents
and young women between 15–19 years old.2–4 Anorexia presents
with distorted body image and food restriction to the point of
severe emaciation or death, likely resulting from a highly
anxiogenic response to intake of palatable foods.5 Although
exhibiting the highest mortality rates among psychiatric illnesses,
with patients facing consequences such as high chronicity and
morbidity, there are no treatments to reverse AN symptoms.6–8
Understanding the pathophysiology of AN has lagged behind
other psychiatric disorders, consequently, eating disorders in
general and AN in particular, have been viewed as non-
biologically based problems of vanity, poor parenting or pertain-
ing to specific groups of individuals.9 Several studies suggest that
genes contribute significantly to neurobiological vulnerabilities,
accounting for approximately 50–75% of the risk for AN.4,10,11
However, the identity of specific genes underlying the disease
remains largely unexplored and the mechanisms are poorly
understood. AN appears to aggregate in families and relatives of
affected individuals seem to have an elevated risk of obsessive-
compulsive personality disorder.12 It is also suggested that first
degree relatives carry a relative risk of 11.3 compared to the
general population,12,13 with mothers showing increased rates of
affective, substance use and anxiety disorders.14 In addition,
various genetic studies have implicated a network of risk-
conferring genes involved in serotonin and dopamine
neurotransmission.15–20 Functional neuroimaging studies corro-
borated these hypotheses19,21–24 by revealing a dysfunctional
dopaminergic (DA) reward circuit in AN.
Despite progress in assigning circuits to neuropsychiatric
disorders, disease-specific molecular and cellular phenotypic data
for regions of interest is either limited, skewed by chronic illness in
post-mortem samples or absent. This problem can now be
addressed by reprogramming somatic cells into a pluripotent
state by ectopic expression of specific genes.25 Such induced
pluripotent stem cells (iPSCs) can be differentiated into neurons
and have been generated for several complex neurological
conditions.26–31 Using this approach, we are able to test
hypotheses and to evaluate whether the captured genome from
human individuals afflicted with AN alters cellular phenotypes as
predicted by mechanistic models of the disease. An AN-iPSC
model may address human-specific effects and avoid some
aspects of the well-known limitations of animal models such as
the absence of a human genetic background.32
Here, we examined the expression profile of human AN-derived
neurons after generating iPSCs from AN patients. We accessed not
only targeted gene expression levels but we also performed whole
transcriptome-based bioinformatics to reveal AN-risk conferring
transcripts/genes that could be associated with disease initiation
and progression. Our study represents a proof-of-concept that AN
can be modeled in vitro. Although no predicted differences at
neurotransmitters levels were observed, we identified a disruption
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of the tachykinin system that might contribute to AN pathophy-
siology before other phenotypes become prominent. While we
believe that further validation using a larger cohort of patients is
important, our work brings a novel technological advancement to
the field of eating disorders. These findings could transform our
ability to study how AN risk-conferring genetic variations perturb
molecular pathways and cellular networks, highlighting potential
approaches for new therapies.
MATERIALS AND METHODS
Participant ascertainment
We isolated and derived fibroblasts from seven females with AN, and four
healthy female controls. The biopsied individuals, control CTL1 and patient
AN1, are sisters. Fibroblast donations were solicited from patients who
were receiving treatment at the outpatient clinic of the UCSD Eating
Disorders Treatment and Research Center. For inclusion, patients had to be
female and meet Diagnostic and Statistical Manual of Mental Disorders, 4th
edition (DSM-IV)33 criteria for AN, except for the amenorrhea criterion. AN
individuals exhibited a stereotypical, post-pubertal onset of weight loss
from self-reducing food intake, fear of weight gain while underweight, with
or without compensatory behaviors such as over-exercise and purging. In
order to reduce a major source of heterogeneity, AN patients were
selected for severity of symptoms and presence of serious medical and
behavioral consequences of AN-related behaviors. This was feasible
because all AN participants were recruited at a tertiary center for
specialized, intensive eating disorders treatment, while receiving treatment
under one of the authors. These recruitment characteristics ensured that
the AN cohort not only met DSM-IV criteria but also met more stringent
and homogeneous medical necessity criteria for severity of illness. AN
individuals in our cohort had a relentless drive to lose weight that had
actually resulted in weight loss. Treatment with their outpatient providers
and efforts at home to restore weight was met with severe emotional
dysregulation and/or medical abnormalities from worsening eating
disordered behaviors. Furthermore, we were able to clearly assess these
symptoms as the parents of the patients were seeking treatment for their
adolescent daughters proximal to onset of their illness. AN individuals who
over-exercised as the only compensatory method as well as others who
used purging via self-induced vomiting, laxatives, among others, were
included. Donations from healthy controls were solicited from siblings of
AN patients along with unaffected individuals participating in other
ongoing research studies. For inclusion, controls had to be female and
should have never met an Axis I diagnosis per DSM-IV. Briefly, fibroblasts
were obtained from skin punch biopsy performed by a Staff Dermatologist
at the UCSD Outpatient Dermatology Clinic. Written informed consent was
acquired from volunteers and their parents (when applicable), and all
human research protocols were approved by the UCSD Institutional
Review Board.
Generation of iPSCs
Skin fibroblasts from 8 individuals, that is, 4 AN patients and 4 controls,
were reprogrammed into iPSCs. Cells were transduced with four retroviral
constructs (OCT4, SOX2, KLF4 and c-MYC), as previously described.25,30
Forming iPSCs were transferred to inactivated mouse embryonic fibroblast
(MEF) feeders in human embryonic stem cell (hESC) medium (DMEM/F12
(Corning, Life Technologies, Carlsbad, CA, USA), 20% Knockout Serum
Replacement (KSR; Life Technologies), 20 ng ml− 1 basic fibroblast growth
factor (bFGF; Life Technologies), 2 mM Glutamax (Gibco, Life Technologies),
1% non-essential aminoacids (NEAA; Sigma-Aldrich, St Louis, MO, USA),
0.1 mM β-mercaptoethanol (Sigma-Aldrich) and 1 mM of valproic acid
(Sigma-Aldrich). hESC-like colonies, characterized by their compact
morphology with a high nucleus-to-cytoplasm ratio, were manually
dissected and passaged to pre-coated Matrigel (BD Biosciences, San Jose,
CA, USA) plates in mTeSR1 medium (Stem Cell Technologies, Vancouver,
BC, Canada). A minimum of 2 iPSC clones from each individual were
selected for expansion.
Karyotyping
Standard G-banding karyotype from fibroblasts and iPSC clones was
performed by the Stem Cell Core Facility at USC (Los Angeles, CA, USA), in
collaboration with the Children’s Hospital Los Angeles.
Teratoma formation
Feeder-free fully grown iPSCs were dissociated with collagenase for 3–
4 min at 37 °C and re-suspended in PBS and Matrigel (1:1). Next, 1–3× 106
cells were injected subcutaneously in the lower hind leg and near the
ankle of immune compromised mice. After 8 weeks, the tumor was
dissected, fixed in 4% paraformaldehyde and paraffin embedded. For
histological studies, sections of 5 μm thickness were stained with
hematoxylin and eosin, and analyzed for the presence of the three
different germ layer tissues. Protocols were approved by the UCSD
Institutional Animal Care and Use Committee.
Embryoid body formation
Assessment of the tri-lineage differentiation capacity of iPSCs was
performed in vitro through embryoid body (EB) formation. Briefly, iPSCs
were mechanically dissociated and cultured in suspension for 14 days in
non-adherent dishes to form EBs in DMEM-F12, 20% FBS. The presence
of the three germ layers was investigated by gene expression
(Supplementary Table S1).
Differentiation of iPSCs into cortical neurons
IPSC medium was changed to N2 medium comprising DMEM/F12 with L-
Glutamine and 15 mM HEPES, 1 ×N2 NeuroPlex (Gemini Bio-Products, West
Sacramento, CA, USA), 1 μM dorsomorphin (R&D System, Minneapolis, MN,
USA) and 10 μM SB431542 (Stemgent, Lexington, MA, USA) for 2 days. Next,
cells were grown in suspension for 7 days in N2 medium. The formed EBs
were gently dissociated and plated onto Matrigel-coated dishes using
neural induction (NI) medium (DMEM/F12 with L-Glutamine and 15 mM
HEPES, 0.5 ×N2 NeuroPlex, 1 ×Gem21 NeuroPlex (Gemini Bio-Products)
and 20 ng ml− 1 bFGF)). Rosettes that emerged were manually picked,
dissociated with Accutase (Life Technologies) and re-plated onto
10 μg ml− 1 Poly-L-ornithine and 5 μg ml− 1 laminin-coated (from Sigma-
Aldrich and Life Technologies, respectively) plates. Homogeneous popula-
tions of neural progenitor cells (NPC) were expanded using NI medium.
The differentiation into neurons was performed upon bFGF withdrawal
and addition of 5 μM ROCK inhibitor (Y-27632, Calbiochem, La Jolla, CA,
USA). Cells were cultivated for 4 weeks with media changes every 3–4 days.
Immunocytochemistry
Cells were fixed with paraformaldehyde, permeabilized and blocked in 3%
bovine serum albumin and 0.1% Triton X-100. Primary antibodies were
incubated overnight at 4 °C; secondary antibodies were incubated for 1 h
at room temperature. Nuclei were stained with DAPI solution (1 μg ml− 1).
Slides were mounted using Prolong Gold antifade reagent (Life
Technologies). Images were captured using a Zeiss microscope (Carl Zeiss,
Jena, Germany). For antibodies specifications, refer to Supplementary
Table S2.
Gene expression analysis
Total RNA was reverse transcribed with QuantiTect Reverse Transcription
Kit (Qiagen, Valencia, CA, USA). To investigate the expression of
pluripotency and the three germ layer genes, cDNA from iPSCs and EBs
was amplified by PCR. qRT-PCR was also performed for selected genes
using specific primers and iQ SYBR Green supermix (Bio-Rad Laboratories,
Irvine, CA, USA). The expression of each target gene and the reference
gene (B2M, beta-2-microglobulin and/or GAPDH, Glyceraldehyde-3-
phosphate dehydrogenase) was measured in technical triplicates for each
reaction. The relative expression quantification was normalized using the
2(−ΔΔCt) method. The AN and control groups were compared by Student’s
t-test. For primer sequences, refer to Supplementary Table S1. The Human
Neurotransmitter Receptors RT2 Profiler PCR Array (#PAHS-060Z;
SABiosciences, Qiagen, Valencia, CA, USA) was used for the quantitative
gene expression analysis of neuronal cultures, as suggested by the
manufacturer.
Western blotting
Twenty micrograms of total protein extracts were separated in Bolt 4–12%
Bis-Tris Plus Gel (Life Technologies) and transferred onto a nitrocellulose
membrane using Thermo Fisher’s iBlot2 dry blotting system. After blocking
(Rockland Immunochemicals, VWR International, Arlington Heights, IL,
USA), membranes were incubated with primary antibodies overnight at
4 °C and then, with secondary antibodies for 1 h at room temperature.
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Proteins were detected using Odyssey CLx infrared imaging system (LI-COR
Biosciences, Lincoln, NE, USA).
Transcriptome analysis
RNA-sequencing (RNA-seq) analysis was performed in 10 μg of total RNA
using Illumina Hiseq-2000 (Illumina, San Diego, CA, USA). Raw sequenced
RNA-seq libraries were filtered for high-quality reads based on read
average quality, and per position nucleotide detection using NGS QC
Toolkit software.34 High-quality reads were mapped to the human
reference genome (Hg19) using Star aligner,35 producing compressed
binary BAM files. Next, binary BAM files were subjected to HTSeq software
package36 to account for absolute number of mapped reads per annotated
transcript (Ensembl GRCh37 annotation) in Hg19, generating a count data
matrix. This matrix was then normalized by a read counting approach
followed by a negative binomial distribution and Fischer’s exact statistical
test for differential expression (DE) analysis using the R Bioconductor
package DESeq.37 For statistical significance calculation between samples,
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false discovery rate based on Benjamini & Hochberg method38 was applied
over the DE genes, with DE transcripts having P-valueo0.05. Count data
was used to calculate Euclidian distance between each pair of samples,
including biological replicates, which were clustered based on shorter
distances. In addition, count data matrix was also used to create a heatmap
together with a hierarchical clustering-based dendrogram, and a two-
component-based Principal Component Analysis (PCA), to show relative
relationship between sequenced AN and control samples in a 2D
coordinate space. For molecular network and functional pathway
annotation robustness, we considered in the analysis only those genes
common to both annotation databanks, ENSEMBL (GRCh38.82) and HUGO
Gene Nomenclature Committee (HGNC). There are 35 644 genes registered
in the HGNC database and 60 619 genes in the ENSEMBL gene annotation
database, with 35 588 genes commonly identified in both databanks.
Gene regulatory networks and functional pathways analyses
The protein–protein interaction network (PIN) was constructed by using
the protein-coding differentially expressed genes (DEGs) and their direct
neighbors (or first-degree interactors). The PIN data were retrieved from
the Biogrid database (v 3.4.127).39 The statistical analysis of network
properties and structure was carried out using Python programming
language and igraph package (igraph.sourceforge.net). Network visualiza-
tion and annotation were performed using Cytoscape40 (http://cytoscape.
org/). ClueGO41 was used to find functional pathways enriched in AN-PIN
based on functional annotation databases such as Gene Ontology42 (GO;
http://geneontology.org/) and Reactome43 (http://www.reactome.org). For
statistical analysis of PINs, we used a computational method published
elsewhere44 to measure two structural properties: average shortest path
length and density of the network. We tested whether the distribution of
those structural properties was similar between AN-PIN and random PIN.
The non-parametric Kolmogorov-Smirnov test as implemented in R (www.
r-project.org) was used to test whether the structural properties of AN-PIN
were similar to random PINs (null hypothesis). The transcriptional profiles
of specific genes in the developing human brain were investigated using
available RNA sequencing data from BrainSpan database (http://www.
brainspan.org).45 These data were generated across 13 developmental
stages in 8–16 brain structures.
RESULTS
Reprogramming somatic cells from AN patients and controls into
iPSCs
All AN patients included in this study had met the DSM-IV criteria
for AN; control individuals (CTL) had never met any Axis I
diagnosis. AN1 and CTL1 are siblings. The phenotypic character-
ization of AN subjects is presented in Figure 1a. A schematic view
of our protocol for iPSC reprogramming and differentiation is
shown in Figure 1b, and the cell types used in each experiment
is detailed in Supplementary Table S3. Two iPSC clones from
4 AN patients and 4 controls, in a total of 16 cell lines, were
mechanically expanded for at least 10 passages and tested for the
expression of the pluripotency markers OCT4 (also known as
POU5F1), TRA-1-60, NANOG and LIN28 (Figure 1c; Supplementary
Figure 1a, b). Apart from sample AN2, which exhibited an extra
structurally abnormal chromosome (ESAC) that was also present in
the original fibroblasts, all iPSC clones derived had maintained a
normal karyotype when analyzed by G-banding (Figure 1d;
Supplementary Figure S1c).
The ability of clones to differentiate into three germ layers was
evaluated in vivo and in vitro. Teratomas showed derivatives from
all three embryonic germ layers (ecto-, meso- and endoderm),
confirming that the iPSCs were pluripotent and able to
differentiate into complex tissues in vivo (Figure 1e). The EBs
generated in suspension were tested by RT-PCR and we observed
that the expression of endogenous pluripotency markers char-
acteristic for hESC were exhibited in all reprogrammed iPSCs
(OCT4, NANOG and LIN28), while genes related with the three
germ layers were only identified in the EBs (AFP, α-fetoprotein—
endoderm; MSX1, Msh homeobox 1—mesoderm; PAX6, paired box
homeotic gene 6—ectoderm; Figure 1f). In addition, considering a
panel of 8 different genes (and their isoforms) associated with
pluripotency, we compared the iPSCs and their fibroblasts
counterparts used for the reprogramming process with a hESC
line (H9; Supplementary Table S4). The high throughput RNA-seq
and bioinformatics data analysis of these cells showed that the
iPSC clones were indistinguishable from hESC lines and were also
very similar to each other, but distinct from primary fibroblast cells
(Figure 1g). Next, by investigating the global transcriptome
expression signatures of these cell types we identified two
subgroups, iPSC/hESC and fibroblasts, which have completely
distinct expression profiles and yet a high degree of similarity
within each subgroup when examined for pluripotency-related
gene markers (Figure 1h). Together, these data show that the
generated iPSC lines successfully re-established pluripotency at
the molecular and cellular levels.
Differentiation of AN and control iPSCs into neurons
For all 16 iPSC clones used in this study, dissociated rosettes
formed a homogenous population of NPCs after a few passages,
that is positive for early precursor markers such as NESTIN,
MUSASHI1 and SOX2 (Figure 2a, Supplementary Figure S1d–f).
Next, we compared the global molecular signatures from iPSC and
neuronal cultures after 4 weeks of differentiation. Two different
gene expression profiles were observed, confirming that we were
able to efficiently differentiate the generated pluripotent cells into
neurons (Figure 2b). The comparison of iPSC, NPC and neurons
according to their levels of expression of OCT4, NESTIN and MAP2
clearly showed that OCT4 was highly expressed in iPSCs but not in
the other cell types, while in progenitor cells and neurons NESTIN
Figure 1. Generation and characterization of iPSCs from AN patients. (a) Patient profile summary. (b) Schematic view and representative
images showing the morphological changes observed during the primary fibroblast cell reprogramming, neural induction and differentiation
processes. Scale bars represent 200 μm. (c) Representative immunofluorescence images illustrating the expression of pluripotency markers in
the generated iPSCs, including OCT4, NANOG, TRA-1–60 and LIN28. Scale bar represents 100 μm. (d) Representative images of G-banding
karyotype analysis from cell chromosomes demonstrating the genetic stability of iPSCs; no karyotypic abnormalities were induced by the
reprogramming process. (e) Representative images of hematoxylin and eosin staining of teratomas derived from iPSCs showing tissues from
the three germ layers. Scale bar represents 100 μm. (f) Expression of pluripotency and three germ layer markers in iPSCs and EBs, respectively,
assessed by RT-PCR (OCT4, NANOG and LIN28—pluripotency; AFP—endoderm; MSX1—mesoderm; PAX6—ectorderm). The H9-hESC was used
as a control for pluripotency and differentiation capability; B2M was used as reference gene. (g) Cluster analysis showing correlation
coefficients of RNA-seq transcripts from iPSCs and hESC, and a distinguished gene expression profile from primary fibroblast cells (FIBRO). A
panel of human pluripotency-related genes (isoform level; Supplementary Table S3) was considered. (h) Heatmap and hierarchical clustering-
based dendrogram of hESC, iPSCs and fibroblasts for AN and control samples. Considering the entire cellular transcriptome expression profile
of evaluated cells, two subgroups were identified: iPSCs, with a molecular signature similar to that exhibited by hESCs, and fibroblasts with a
completely different expression profile. In g and h, colors indicate the range of each gene’s expression, with least expression shown in red and
highest expression shown in green. AN, anorexia nervosa; anxiety, patient showed/treated for anxiety; CTL, control (unaffected individual);
famhx-ED, first, second or third degree relative with a history of an eating disorder; fi, fibroblast; iPSC, induced pluripotent stem cell;
MDD, major depressive disorder; neu, neurons; NPC, neural progenitor cell; OCD, obsessive compulsive disorder; psychotropic, patient was
prescribed at least one psychotropic medication.
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and MAP2 were preferentially upregulated, respectively (Figure 2c).
Using the described protocol, NPC differentiation gave rise to a
mature population of cortical human neurons expressing MAP2,
GFAP, NEUN and CTIP2 (also known as BCL11B; cortical layer V;
Figures 2d and e; Supplementary Figure S1g). Moreover, in these
differentiated cultures we also detected the presence of both
excitatory glutamatergic pyramidal-shaped neurons (VGLUT1 and
SYN1) and inhibitory GABAergic interneurons (GAD65-67 and
Figure 2. Derivation of neural progenitor cells and neurons from AN-iPSCs. (a) Representative images showing that the neural progenitor
stage-specific markers NESTIN and SOX2 are expressed by AN iPSC-derived NPCs. Scale bar represents 100 μm. (b) Cluster analysis showing
that after 4 weeks of differentiation neurons (NE) exhibit a molecular signature distinct from that of their iPSC counterparts. Colors indicate
the range of each gene’s expression, with least expression shown in red and highest expression shown in green. (c) Gene expression changes
observed during the differentiation process measured by qRT-PCR using stage-specific markers for iPSCs (OCT4), NPCs (NESTIN) and neurons
(MAP2). The expression levels of each gene were quantified, normalized to B2M (reference gene), and the results are presented as mean± s.e.
m. (n⩾ 8 for each group). (d) Representative immunofluorescence images of cells after neuronal differentiation. IPSC-derived neural cultures
express neuronal (MAP2, NEUN) and glial (GFAP) markers, together with specific cortical proteins (CTIP2). Excitatory (VGLUT1 and SYN1) and
inhibitory (GAD65-67 and GABA) neuronal proteins are also observed in the generated neural population. The presence of LMX1A and FOXA2
among the neuronal cells, although low, is an evidence of the dopaminergic neuronal fate. Scale bar represents 100 μm. (e) Quantification of
the percentage of MAP2+ (neuron), VGLUT1+ (glutamatergic), GABA+ (GABAergic) and GFAP+ (glia) labeled cells is presented as mean± s.e.m.
(n⩾ 8 for each group). (f) Representative western blotting of control and AN-derived neural proteins that were lysed and immunoblot for
neuronal (TUJ1, VGLUT1, GAD65-67, PSD95, SYN1 and TH) and glial (GFAP) markers, along with the dopamine transporter (DAT); β-ACTIN was
used as housekeeping control (reference). (g) Quantification of proteins in AN and control neural cultures assessed by Western blot analysis; β-
ACTIN was used for normalization (n= 8 for each group). No differences were observed between control and affected samples (Po0.05,
Student’s t-test). AN, anorexia nervosa; iPSC, induced pluripotent stem cell; NPC, neural progenitor cells.
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Figure 3. Transcriptional analysis of AN iPSC-derived neuronal cultures. (a) Heatmap and the hierarchical clustering-based dendrogram of
samples after 4 weeks of differentiation. No significant differences are observed between iPSC-derived neurons (NE) from AN patients and
controls. (b) Heatmap and the hierarchical clustering-based dendrogram displaying the transcriptional pattern of genes associated with neural
development and differentiation in AN and control neural cultures (list of genes at Supplementary Table S5). (c) Heatmap and hierarchical
clustering-based dendrogram of genes with minimum fold-change variation of 2 and false discovery rate (FDR)-adjusted P-valueo0.01
between AN and control neurons. (d) Neuronal specific cell type-based clustering analysis of AN and control samples using 13 selected
candidate genes most differentially expressed between the two subgroups (Po0.01). In all heatmaps (a–d), colors indicate the range of each
gene’s expression, with least expression shown in red and highest expression shown in green. (e) Validation of 13 selected candidate genes
from the RNA-seq analysis by qRT-PCR. Downregulated (red histogram) or upregulated (green histogram) genes differentially expressed
between AN and control neurons. Independent neuronal cultures generated from the same clones used in the RNA-seq analysis were used in
this validation; GAPDH was used as reference gene. Error bars are represented by standard deviation. (f) Topological structure of AN-PIN and
random-PIN showing that AN-PIN is denser and with smaller shortest path than random-PIN (Kolmogorov–Smirnov test, Po0.01). (g) Enriched
GO functional pathways terms found in neurons derived from AN patients (the complete list is found in the Supplementary Table S8). (h)
Volcano plot of PCR array analysis for human neurotransmitter receptors. Plot illustrates that although control and AN-derived neurons do not
show significant differences in expression for estrogen receptors and dopamine/serotonin neurotransmitter systems constituents, the TACR1
gene is upregulated in AN neurons (2.0-fold differential expression between the groups at Po0.05; Student’s t-test). (i) Upper panel:
representative western blotting of control and AN-derived neural proteins that were lysed and immunoblot for TACR1; β-ACTIN was used as
reference. Bottom panel: quantification of TACR1 protein in AN and control neural cultures assessed by Western blot analysis. Increased levels
of TACR1 were observed in AN (Po0.05, Student’s t-test). Proteins were detected using Odyssey CLx infrared imaging system. (j) BrainSpan
analysis of the TACR1 gene in brain regions from striatal networks. RNA-seq RPKM (reads per kilobase per million) identified during the
different stages of human brain development. ACC, anterior cingulate cortex; AN, anorexia nervosa; iPSC, induced pluripotent stem cell;
MNT, mediodorsal nucleus of thalamus; OFC, orbital frontal cortex; STR, striatum; VPC, ventrolateral prefrontal cortex.
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GABA) along with LMX1A and FOXA2 positive cells, which are
selectively expressed in progenitors committed to the generation
of midbrain dopaminergic neurons (Figure 2d and e;
Supplementary Figure S1g-i). Western blot analysis corroborated
the immunostaining results and confirmed that the overall
composition of neuronal cultures does not change between
controls and AN patients (Figures 2f and g; Supplementary Figure
S2a, c).
Gene expression profile of iPSC-derived neurons
After 4 weeks of differentiation, the gene expression profile of AN
neurons and controls was investigated. A total of 24 944 genes
were found to be transcribed in the iPSC-derived neurons from AN
patients and healthy individuals; 361 DEGs (156 upregulated and
205 down-regulated) were identified in AN compared to controls.
The DEGs are annotated as four locus groups: 248 protein-coding
genes, 50 non-coding RNAs, 57 pseudogenes and 6 others
(Supplementary Table S5). The global molecular signature
obtained after RNA-seq showed that both neuronal populations
are very similar (Figure 3a). When we narrowed down this analysis
considering only a panel of genes related to neural development
and differentiation, no significant differences were observed
(Figure 3b; Supplementary Table S6) suggesting that noticeable
developmental anomalies might not be present in AN patients’
brain. After considering genes differentially expressed between
affected and unaffected subjects with a statistical significance of
95% (fold change⩾2, Po0.05, 545 genes; Supplementary Table
S7), we increased the stringency of our analysis by including only
targets with 99% significance (fold-change⩾ 2, Po0.01, 110
genes; Supplementary Table S8) and found that AN samples
cluster together in a subgroup different from that of control
individuals (Figure 3c). Interestingly, when 13 candidate genes
were selected based on their altered expression in AN with fold-
change variation of 2 or more, the clustering algorithm produced
subgroups with affected and control samples that remained
distinct (Figure 3d). We validated the RNA-seq results for these 13
genes by qRT-PCR and confirmed the same expression patterns
observed in the transcriptome analysis (Figure 3e), suggesting that
such genes might contribute to the anorexic phenotype.
To identify functional pathways and molecular interactions
associated with DEGs in AN neurons, we first built a protein-
protein interaction network (PIN) using the 248 protein-coding
DEGs (Po0.01; Supplementary Table S5) and their direct
neighbors (first-degree interactors). Approximately 68% of DEGs
(168) were found in the protein-protein interaction database and
the AN-PIN is comprised of 1492 proteins and 2254 interactions.
The topological structure of AN-PIN is different from PIN built out
of randomly selected genes indicating that DEGs in AN have
higher connectivity than expected by chance (Kolmogorov-
Smirnov test D= 0.81, Po0.01), and smaller average shortest
path (Kolmogorov–Smirnov test D= 0.41, Po0.01; Figure 3f).
These data suggest that proteins encoded by co-expressed genes
in AN subjects are significantly more inter-connected and are
likely to be associated with closely related molecular pathways
including TACR1 (tachykinin receptor 1) signaling, regulation of
synaptic transmission through the cholinergic system and
response to estrogen, among others (Fisher’s exact test with
Bonferroni correction Po0.01; Figure 3g; Supplementary Table
S9).
Several neurotransmitters and peptides, or their metabolites,
can potentially contribute to the AN phenotype, including weight
loss, feeding regulation and the reward system.15,22,46,47 Then,
based on the enriched pathways revealed by the DEGs of our
sample cohort, we decided to investigate the neurotransmitter
profile of AN-derived neuronal cultures using a PCR array platform.
This approach was complemented by the addition of specific
targets pertaining to the dopaminergic pathway, estrogen
receptors and tachykinin signaling (Supplementary Table S1).
Notably, both control and AN neurons are very similar except by
the expression of the TACR1 gene, also known as NK1R (neurokinin
1 receptor) or SPR (substance P receptor), which was significantly
upregulated in AN (Figure 3h). In confirmatory studies, the TACR1
gene was found upregulated after RNA-seq analysis with a
significance of 95% (Supplementary Table S7), while the TAC1
(tachykinin precursor 1) gene had a reduced expression of almost
two fold-change (Supplementary Table S7 and S8) in AN neuronal
samples. The protein levels of TACR1 were also increased in AN
neurons compared to controls (Student’s t-test, Po0.05; Figure 3i;
Supplementary Figure S2a, b). Furthermore, the BrainSpan analysis
of the TACR1 gene within brain regions associated with striatal
networks showed its expression peaks during adolescence, the
stage of human development in which AN has its onset (Figure 3j).
Although TACR1 has previously been associated with psychiatric
disorders, we believe this is the first report of its contribution
to AN.
DISCUSSION
AN is a severe psychiatric disorder that still lacks effective
treatments.7,8 Several studies have been conducted aiming to
identify the genetic basis of AN. Genome-wide association
approaches (GWAS) have emerged as a promising tool for genetic
screening. Even though single-nucleotide polymorphisms and/or
copy-number variations have been identified, these findings
require further analysis in independent cohorts and no study
was powerful enough to robustly link specific genes with
AN.10,48–52 The difficulty in validating potential candidates likely
arises from the need for large sample populations, which is
particularly difficult for uncommon disorders like AN, that has an
incidence far o1% of adolescents. Therefore, the genetic
underlying AN susceptibility remains largely unknown. The
literature in AN is mostly derived from DNA-based assays
performed in blood samples or animal models. In this context,
the ability to perform a transcriptome analysis to uncover genes
implicated in AN pathophysiology using human neural cells could
provide a major advantage toward understanding the etiology of
the disorder.
Following the reprogramming of skin fibroblasts into iPSCs, we
generated neural cultures that allowed us to investigate the gene
expression profile of neurons derived from AN patients. The global
molecular signature of neurons after RNA-seq analysis showed
that AN and control cultures are, overall, very similar to each other.
However, two subgroups were identified via a high-stringency
analysis using differentially expressed genes with a statistical
significance of 99% between affected and unaffected individuals.
Among the misregulated genes found, CTGF (connective tissue
growth factor), which is critical for normal ovarian follicle
development and ovulation,53 was downregulated in AN samples.
This result is congruent with the amenorrhea symptom typically
observed in patients.54 The misregulation of CTGF in our cohort,
despite not using amenorrhea as a diagnostic criterion, might
serve as preliminary support for omission of this criterion. The
lower expression of TDRD10 (tudor domain containing 10) could
also contribute to AN pathophysiology, since the TDRD family of
proteins is known to be relevant for gametogenesis55 and
anorexics became at least temporarily infertile.56 Interestingly,
the FABP12 (Fatty-acid Binding Protein 12) gene, which is related
to lipid metabolism as other FABP members,57 was downregulated
in AN-neural cultures, accompanied by high expression levels of
TSHR. Since TSHR is detected in preadipocytes and adipocytes,58,59
and was shown to participate in adipogenesis,60 disruption in this
gene was already associated with body weight and energy
consumption problems.61 Chen et al.62 demonstrated that
increased TSHR inhibits FASN (fatty acid synthase) expression or
energy storage in mature adipocytes, showing that impairments in
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TSH/TSHR signaling could participate in the development of
obesity. In the same way, the DGKG (Diacylglycerol Kinase Gamma)
gene, that had been associated with chronic stress63 and
obesity,64 was found upregulated in AN-neurons. These findings
suggest that misregulation of several genes, primarily unrelated,
could contribute to the genesis and/or symptomatology of this
multifactorial disease in a synergistic manner.
Despite the limitation of GWAS in finding statistical significance
for risk-conferring genes in AN, a variety of studies have identified
the serotonin and dopamine systems as major players in the
pathophysiology of the disease.20–22,65,66,67 However, the literature
remains unsettled regarding these hypotheses.68,69 Since mood
and motor activity, food intake, decision-making abilities, reinfor-
cement and reward are features directly affected by disruptions in
the serotonin and/or dopamine pathways, we decided to
investigate not only these systems but a broader neurotransmitter
expression profile in neurons derived from AN patients. No
substantial expression changes were found either among
serotonin- nor among dopamine-related genes in our culture
system. Notably, the expression of TACR1 was significantly
upregulated in AN. This G-protein coupled receptor (GPCR) is
distributed in many areas of the human brain including the frontal
cortex,70 the amygdala and striatum,71 and has high affinity for
Substance P (SP), the most abundant tachykinin (or neurokinin)
that participates in the regulation of a variety of biological
functions.72,73
Several studies have reported the contribution of TACR1 to
affective, anxiety and motivated disorders such as addictive
behavior,74 bipolar disorder,75–77 attention deficit hyperactivity
disorder,75,78 depression,79,80 fear81,82 and anxiety.73,81,83–85 AN
presents as a motivated disorder with anxiety3 induced by
palatable food and is frequently comorbid with mood
symptoms,3 especially while the patient is underweight. While
TACR1 has been implicated in a variety of animal models that
recapitulate core phenotypes of AN such as heightened anxiety
and hyperactivity,78,86,87 absence of TACR1 also increases risk for
high body mass index in a sex-dependent manner in mice.88
Conversely, increased TACR1 expression in human females with
AN presumably increases risk for low body mass index. Among its
diverse biological roles, TACR1 antagonists have been developed
to treat emesis and reduction in food intake in those receiving
cisplatin chemotherapy.89 Mechanistically, TACR1 and SP have
been shown to interact with the monoaminergic system70,83,90,91
and to modulate the reward pathway.92,93 Notably, the Brainspan
atlas show TACR1 expression peaking during adolescence in the
striatum, a brain region implicated in impaired reward processing
in AN. The onset of AN is during adolescence and brain imaging
studies reveal structural and functional abnormalities in striatal
networks.94 The pharmacology of reversing phenotypes in TACR1
models and use of dopamine antagonists in the treatment of AN
share a common mechanism of targeting the dopaminergic
system. Interestingly, a study in Caenorhabditis elegans showed
that a tachykinin neuroendocrine signalling mediates body fat
loss, by connecting the neural serotonin circuit to its metabolic
actions in the intestine.95 Thus, many aspects of the disease
onset and symptoms could be associated with misregulated
tackykinins, including the serotonin and dopamine imbalances78
observed in AN clinical studies,19,21,22 especially due to the overlap
and functional interaction of monoamines and SP in the
brain.92,96–98
In summary, we have developed a new human cellular model of
AN and performed a complete and systematic transcriptional
analysis of human AN-derived neurons. Despite using a small
cohort, our study identified TACR1, a member of the tachykinin
family that has previously been associated with other psychiatric
disorders, dysregulated in AN. This gene arises as an unexplored
target that potentially contributes to the pathophysiology of AN
and that might be compromised in patients before other
neurotransmitter systems are disrupted. Nonetheless, it is
noteworthy that while our approach represents an innovative
tool for understanding the molecular and genetic mechanisms
contributing to AN, there is a caveat since the reprogramming
process can alter the epigenetic memory of cells. If such
alterations participate in the disease, they could be under-
estimated here and should be addressed in future studies.
Improvements in the efficacy of current treatments and develop-
ment of new therapies have been hampered by a lack of
knowledge of the neurobiology of AN. Then, identifying novel
molecular pathways altered in this complex disorder will provide
an opportunity for new diagnostic strategies and treatments. Our
study represents a proof-of-concept that AN can be modeled
in vitro. Although our findings should be confirmed in a broader
cohort of patients in the future, we believe that some features
attributed to serotonin and/or dopamine pathways could be a
consequence of a mis-regulated tachykinin system, ultimately
affecting mood, food intake, lipid metabolism, anxiety and reward
behaviors in AN individuals.
CONFLICT OF INTEREST
The authors declare no conflict of interest.
ACKNOWLEDGMENTS
We thank Dr Anna Di Nardo for gently collecting all skin biopsies used in this study.
We thank Dr Brian Tobe for helpful discussions and critiques on using stem cells in
psychiatry. The Muotri lab is supported by grants from the California Institute for
Regenerative Medicine (CIRM) TR4-06747, the National Institutes of Health through
the NIH Director's New Innovator Award Program (1-DP2-OD006495-01), an R21
1R21MH093954; and a NARSAD Independent Investigator Grant to ARM.
AUTHOR CONTRIBUTIONS
ARM and PDN designed the experiments with input from all authors and wrote
the manuscript. PDN, FRC and TC generated and characterized the iPSCs. PDN
and FRC generated and characterized NPCs and neuronal populations. PDN
performed all gene expression/protein assays and statistical analysis with help
from FRC. CAT performed PCR array analysis. RHH and ASC performed all
bioinformatics analysis. VD helped to design the experiments and analysis, and
co-wrote the manuscript with ARM and PDN. All authors reviewed the
manuscript for publication.
REFERENCES
1 Smink FRE, van Hoeken D, Hoek HW. Epidemiology of eating disorders: incidence,
prevalence and mortality rates. Curr Psychiatry Rep 2012; 14: 406–414.
2 Clarke TK, Weiss a RD, Berrettini WH. The genetics of anorexia nervosa. Clin
Pharmacol Ther 2012; 91: 181–188.
3 Guarda AS, Schreyer CC, Boersma GJ, Tamashiro KL, Moran TH. Anorexia nervosa
as a motivated behavior: Relevance of anxiety, stress, fear and learning. Physiol
Behav 2015; 152: 466–472.
4 Bulik CM, Sullivan PF, Tozzi F, Furberg H, Lichtenstein P, Pedersen NL. Prevalence,
heritability, and prospective risk factors for anorexia nervosa. Arch Gen Psychiatry
2006; 63: 305–312.
5 Sharan P, Sundar AS. Eating disorders in women. Indian J Psychiatry 2015; 57:
S286–S295.
6 Arcelus J, Mitchell AJ, Wales J, Nielsen S. Mortality rates in patients with anorexia
nervosa and other eating disorders. A meta-analysis of 36 studies. Arch Gen
Psychiatry 2011; 68: 724–731.
7 Bulik CM, Berkman ND, Brownley KA, Sedway JA, Lohr KN. Anorexia nervosa
treatment: a systematic review of randomized controlled trials. Int J Eat Disord
2007; 40: 310–320.
8 Watson HJ, Bulik CM. Update on the treatment of anorexia nervosa: review of
clinical trials, practice guidelines and emerging interventions. Psychol Med 2013;
43: 2477–2500.
9 O’Hara SK, Smith KC. Presentation of eating disorders in the news media: What are
the implications for patient diagnosis and treatment? Patient Educ Couns 2007; 68:
43–51.
Modeling anorexia nervosa using iPSCs
PD Negraes et al
8
Translational Psychiatry (2017), 1 – 10
10 Wang K, Zhang H, Bloss CS, Duvvuri V, Kaye W, Schork NJ et al. A genome-wide
association study on common SNPs and rare CNVs in anorexia nervosa. Mol
Psychiatry 2011; 16: 949–959.
11 Brandys MK, de Kovel CG, Kas MJ, van Elburg AA, Adan RA. Overview of genetic
research in anorexia nervosa: the past, the present and the future. Int J Eat Disord
2015; 48: 814–825.
12 Lilenfeld LR, Kaye WH, Greeno CG, Merikangas KR, Plotnicov K, Pollice C et al. A
controlled family study of anorexia nervosa and bulimia nervosa: psychiatric
disorders in first-degree relatives and effects of proband comorbidity. Arch Gen
Psychiatry 1998; 55: 603–610.
13 Strober M. Controlled family study of anorexia nervosa and bulimia nervosa:
evidence of shared liability and transmission of partial syndromes. Am J Psychiatry
2000; 157: 393–401.
14 Rost S, Kappel V, Salbach H, Schneider N, Pfeiffer E, Lehmkuhl U et al. Psychiatric
disorders and personality styles in mothers of female adolescent patients with eating
disorders. Z Kinder Jugendpsychiatr Psychother 2016; 1–9 (e-pub ahead of print).
15 Kaye WH, Frank GK, Bailer UF, Henry SE. Neurobiology of anorexia nervosa: Clinical
implications of alterations of the function of serotonin and other neuronal sys-
tems. Int J Eat Disord 2005; 37: S15–S19.
16 Rask-Andersen M, Olszewski PK, Levine AS, Schiöth HB. Molecular mechanisms
underlying anorexia nervosa: focus on human gene association studies and sys-
tems controlling food intake. Brain Res Rev 2010; 62: 147–164.
17 Kaye WH, Gwirtsman HE, George DT, Jimerson DC, Ebert MH. CSF 5-HIAA con-
centrations in anorexia nervosa: reduced values in underweight subjects nor-
malize after weight gain. Biol Psychiatry 1988; 23: 102–105.
18 Phillipou A, Rossell SL, Castle DJ. The neurobiology of anorexia nervosa: a
systematic review. Aust N Z J Psychiatry 2014; 48: 128–152.
19 Kaye WH, Frank GK, McConaha C. Altered dopamine activity after recovery
from restricting-type anorexia nervosa. Neuropsychopharmacology 1999; 21:
503–506.
20 Gervasini G, Gordillo I, García-Herráiz A, Flores I, Jiménez M, Monge M et al.
Influence of dopamine polymorphisms on the risk for anorexia nervosa and
associated psychopathological features. J Clin Psychopharmacol 2013; 33:
551–555.
21 Frank GK, Kaye WH, Meltzer CC, Price JC, Greer P, McConaha C et al. Reduced
5-HT2A receptor binding after recovery from anorexia nervosa. Biol Psychiatry
2002; 52: 896–906.
22 Frank GK, Bailer UF, Henry SE, Drevets W, Meltzer CC, Price JC et al. Increased
dopamine D2/D3 receptor binding after recovery from anorexia nervosa mea-
sured by positron emission tomography and [11c]raclopride. Biol Psychiatry 2005;
58: 908–912.
23 Wagner A, Aizenstein H, Venkatraman VK, Fudge J, May JC, Mazurkewicz L et al.
Altered reward processing in women recovered from anorexia nervosa. Am J
Psychiatry 2007; 164: 1842–1849.
24 Kaye WH, Gwirtsman HE, George DT, Ebert MH. Altered serotonin activity in
anorexia nervosa after long-term weight restoration. Does elevated cerebrospinal
fluid 5-hydroxyindoleacetic acid level correlate with rigid and obsessive behavior?
Arch Gen Psychiatry 1991; 48: 556–562.
25 Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K et al. Induction
of pluripotent stem cells from adult human fibroblasts by defined factors. Cell
2007; 131: 861–872.
26 Marchetto MCN, Carromeu C, Acab A, Yu D, Yeo GW, Mu Y et al. A model for
neural development and treatment of Rett syndrome using human induced
pluripotent stem cells. Cell 2010; 143: 527–539.
27 Mitne-Neto M, Machado-Costa M, Marchetto MCN, Bengtson MH, Joazeiro CA,
Tsuda H et al. Downregulation of VAPB expression in motor neurons derived from
induced pluripotent stem cells of ALS8 patients. Hum Mol Genet 2011; 20:
3642–3652.
28 Andrade LN, de S, Nathanson JL, Yeo GW, Menck CFM, Muotri AR. Evidence for
premature aging due to oxidative stress in iPSCs from Cockayne syndrome. Hum
Mol Genet 2012; 21: 3825–3834.
29 Nageshappa S, Carromeu C, Trujillo CA, Mesci P, Espuny-Camacho I, Pasciuto E
et al. Altered neuronal network and rescue in a human MECP2 duplication model.
Mol Psychiatry 2015; 21: 178–188.
30 Griesi-Oliveira K, Acab A, Gupta AR, Sunaga DY, Chailangkarn T, Nicol X et al.
Modeling non-syndromic autism and the impact of TRPC6 disruption in human
neurons. Mol Psychiatry 2015; 20: 1350–1365.
31 Chailangkarn T, Trujillo CA, Freitas BC, Hrvoj-Mihic B, Herai RH, Yu DX et al. A
human neurodevelopmental model for Williams syndrome. Nature 2016; 536:
338–343.
32 Gutierrez E. A rat in the labyrinth of anorexia nervosa: contributions of the
activity-based anorexia rodent model to the understanding of anorexia nervosa.
Int J Eat Disord 2013; 46: 289–301.
33 Association AP Diagnostic and Statistical Manual of Mental Disorders, 4th edn.
American Psychiatric Association: Washington, DC: 1994.
34 Patel RK, Jain M. NGC QC Toolkit: a toolkit for quality control of next generation
sequencing data. PLoS ONE 2012; 7: e30619.
35 Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S et al. STAR: ultrafast
universal RNA-seq aligner. Bioinformatics 2013; 29: 15–21.
36 Anders S, Pyl PT, Huber W. HTSeq - a Python framework to work with high-
throughput sequencing data. Bioinformatics 2014; 31: 166–169.
37 Anders S, Huber W. Differential expression analysis for sequence count data.
Genome Biol 2010; 11: R106.
38 Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and
powerful approach to multiple testing. J R Stat Soc Ser B 1995; 57: 289–300.
39 Stark C, Breitkreutz B-J, Reguly T, Boucher L, Breitkreutz A, Tyers M. BioGRID: a
general repository for interaction datasets. Nucleic Acids Res 2006; 34: D535–D539.
40 Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D et al. Cytoscape: a
software environment for integrated models of biomolecular interaction net-
works. Genome Res 2003; 13: 2498–2504.
41 Bindea G, Mlecnik B, Hackl H, Charoentong P, Tosolini M, Kirilovsky A et al.
ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and
pathway annotation networks. Bioinformatics 2009; 25: 1091–1093.
42 Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM et al. Gene
ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat
Genet 2000; 25: 25–29.
43 Croft D, Mundo AF, Haw R, Milacic M, Weiser J, Wu G et al. The Reactome pathway
knowledgebase. Nucleic Acids Res 2014; 42: D472–D477.
44 Cristino AS, Williams SM, Hawi Z, An J-Y, Bellgrove MA, Schwartz CE et al. Neu-
rodevelopmental and neuropsychiatric disorders represent an interconnected
molecular system. Mol Psychiatry 2014; 19: 294–301.
45 Miller JA, Ding S-L, Sunkin SM, Smith KA, Ng L, Szafer A et al. Transcriptional
landscape of the prenatal human brain. Nature 2014; 508: 199–206.
46 Kaye WH, Ebert MH, Raleigh M, Lake R. Abnormalities in CNS monoamine
metabolism in anorexia nervosa. Arch Gen Psychiatry 1984; 41: 350–355.
47 Kaye W. Neurobiology of anorexia and bulimia nervosa. Physiol Behav 2008; 94:
121–135.
48 Boraska V, Davis OSP, Cherkas LF, Helder SG, Harris J, Krug I et al. Genome-wide
association analysis of eating disorder-related symptoms, behaviors, and
personality traits. Am J Med Genet B Neuropsychiatr Genet 2012; 159B: 803–811.
49 Wade TD, Gordon S, Medland S, Bulik CM, Heath AC, Montgomery GW et al.
Genetic variants associated with disordered eating. Int J Eat Disord 2013; 46:
594–608.
50 Boraska V, Franklin CS, Floyd J a B, Thornton LM, Huckins LM, Southam L et al. A
genome-wide association study of anorexia nervosa. Mol Psychiatry 2014; 19:
1085–1094.
51 Guo Y, Wei Z, Keating BJ, Hakonarson H. Machine learning derived risk prediction
of anorexia nervosa. BMC Med Genomics 2016; 9: 4.
52 Wang K, Zhang H, Bloss CS, Duvvuri V, Kaye W, Schork NJ et al. A genome-wide
association study on common SNPs and rare CNVs in anorexia nervosa. Mol
Psychiatry 2011; 16: 949–959.
53 Nagashima T, Kim J, Li Q, Lydon JP, DeMayo FJ, Lyons KM et al. Connective tissue
growth factor is required for normal follicle development and ovulation. Mol
Endocrinol 2011; 25: 1740–1759.
54 Bulik CM, Reba L, Siega-Riz A-M, Reichborn-Kjennerud T. Anorexia nervosa: defi-
nition, epidemiology, and cycle of risk. Int J Eat Disord 2005; 37(Suppl): S2–9–1.
55 Hosokawa M, Shoji M, Kitamura K, Tanaka T, Noce T, Chuma S et al. Tudor-related
proteins TDRD1/MTR-1, TDRD6 and TDRD7/TRAP: domain composition, intracel-
lular localization, and function in male germ cells in mice. Dev Biol 2007; 301:
38–52.
56 Katz MG, Vollenhoven B. The reproductive endocrine consequences of anorexia
nervosa. BJOG 2000; 107: 707–713.
57 Smathers RL, Petersen DR. The human fatty acid-binding protein family: evolu-
tionary divergences and functions. Hum Genomics 2011; 5: 170–191.
58 Crisp MS, Lane C, Halliwell M, Wynford-Thomas D, Ludgate M. Thyrotropin
receptor transcripts in human adipose tissue. J Clin Endocrinol Metab 1997; 82:
2003–2005.
59 Haraguchi K, Shimura H, Lin L, Endo T, Onaya T. Differentiation of rat pre-
adipocytes is accompanied by expression of thyrotropin receptors. Endocrinology
1996; 137: 3200–3205.
60 Lu M, Lin R-Y. TSH stimulates adipogenesis in mouse embryonic stem cells. J
Endocrinol 2008; 196: 159–169.
61 Mullur R, Liu Y-Y, Brent GA. Thyroid hormone regulation of metabolism. Physiol
Rev 2014; 94: 355–382.
62 Chen J, Ren J, Jing Q, Lu S, Zhang Y, Liu Y et al. TSH/TSHR Signaling Suppresses
Fatty Acid Synthase (FASN) Expression in Adipocytes. J Cell Physiol 2015; 230:
2233–2239.
63 Lisowski P, Wieczorek M, Goscik J, Juszczak GR, Stankiewicz AM, Zwierzchowski L
et al. Effects of chronic stress on prefrontal cortex transcriptome in mice dis-
playing different genetic backgrounds. J Mol Neurosci 2013; 50: 33–57.
Modeling anorexia nervosa using iPSCs
PD Negraes et al
9
Translational Psychiatry (2017), 1 – 10
64 Cheung CYY, Tso AWK, Cheung BMY, Xu A, Ong KL, Fong CHY et al. Obesity
susceptibility genetic variants identified from recent genome-wide association
studies: implications in a chinese population. J Clin Endocrinol Metab 2010; 95:
1395–1403.
65 Bailer UF, Frank GK, Price JC, Meltzer CC, Becker C, Mathis CA et al. Interaction
between serotonin transporter and dopamine D2/D3 receptor radioligand
measures is associated with harm avoidant symptoms in anorexia and bulimia
nervosa. Psychiatry Res 2013; 211: 160–168.
66 O’Hara CB, Keyes A, Renwick B, Leyton M, Campbell IC, Schmidt U. The effects of
acute dopamine precursor depletion on the reinforcing value of exercise in
anorexia nervosa. PLoS One 2016; 11: e0145894.
67 Frieling H, Römer KD, Scholz S, Mittelbach F, Wilhelm J, De Zwaan M et al.
Epigenetic dysregulation of dopaminergic genes in eating disorders. Int J Eat
Disord 2010; 43: 577–583.
68 Broft A, Slifstein M, Osborne J, Kothari P, Morim S, Shingleton R et al. Striatal
dopamine type 2 receptor availability in anorexia nervosa. Psychiatry Res 2015;
233: 380–387.
69 Södersten P, Bergh C, Leon M, Zandian M. Dopamine and anorexia nervosa.
Neurosci Biobehav Rev 2015; 60: 26–30.
70 Nagano M, Saitow F, Haneda E, Konishi S, Hayashi M, Suzuki H. Distribution and
pharmacological characterization of primate NK-1 and NK-3 tachykinin receptors
in the central nervous system of the rhesus monkey. Br J Pharmacol 2006; 147:
316–323.
71 Engman J, Åhs F, Furmark T, Linnman C, Pissiota A, Appel L et al. Age, sex and NK1
receptors in the human brain -- a positron emission tomography study with [11C]
GR205171. Eur Neuropsychopharmacol 2012; 22: 562–568.
72 Garcia-Recio S, Gascón P. Biological and pharmacological aspects of the NK1-
receptor. Biomed Res Int 2015; 2015: 495704.
73 Muñoz M, Coveñas R. Involvement of substance P and the NK-1 receptor in
human pathology. Amino Acids 2014; 46: 1727–1750.
74 Schank JR. The neurokinin-1 receptor in addictive processes. J Pharmacol Exp Ther
2014; 351: 2–8.
75 Sharp SI, McQuillin A, Marks M, Hunt SP, Stanford SC, Lydall GJ et al. Genetic
association of the tachykinin receptor 1 TACR1 gene in bipolar disorder, attention
deficit hyperactivity disorder, and the alcohol dependence syndrome. Am J Med
Genet B Neuropsychiatr Genet 2014; 165B: 373–380.
76 Amoruso A, Bardelli C, Cattaneo CI, Fresu LG, Manzetti E, Brunelleschi S. Neuro-
kinin (NK)-1 receptor expression in monocytes from bipolar disorder patients: a
pilot study. J Affect Disord 2015; 178: 188–192.
77 Perlis RH, Purcell S, Fagerness J, Kirby A, Petryshen TL, Fan J et al. Family-based
association study of lithium-related and other candidate genes in bipolar dis-
order. Arch Gen Psychiatry 2008; 65: 53–61.
78 Yan TC, McQuillin A, Thapar A, Asherson P, Hunt SP, Stanford SC et al. NK1 (TACR1)
receptor gene ‘knockout’ mouse phenotype predicts genetic association
with ADHD. J Psychopharmacol 2010; 24: 27–38.
79 Burnet PW, Harrison PJ. Substance P (NK1) receptors in the cingulate cortex in
unipolar and bipolar mood disorder and schizophrenia. Biol Psychiatry 2000; 47:
80–83.
80 Frisch P, Bilkei-Gorzó A, Rácz I, Zimmer A. Modulation of the CRH system by
substance P/NKA in an animal model of depression. Behav Brain Res 2010; 213:
103–108.
81 Brenes JC, Broiz AC, Bassi GS, Schwarting RKW, Brandão ML. Involvement of
midbrain tectum neurokinin-mediated mechanisms in fear and anxiety. Braz J
Med Biol Res 2012; 45: 349–356.
82 Carvalho MC, Santos JM, Bassi GS, Brandão ML. Participation of NK1 receptors of
the amygdala on the processing of different types of fear. Neurobiol Learn Mem
2013; 102: 20–27.
83 Santarelli L, Gobbi G, Debs PC, Sibille ET, Blier P, Hen R et al. Genetic and phar-
macological disruption of neurokinin 1 receptor function decreases anxiety-
related behaviors and increases serotonergic function. Proc Natl Acad Sci U S A
2001; 98: 1912–1917.
84 Bassi GS, de Carvalho MC, Brandão ML. Effects of substance P and Sar-Met-SP, a
NK1 agonist, in distinct amygdaloid nuclei on anxiety-like behavior in rats. Neuro-
sci Lett 2014; 569: 121–125.
85 Ebner K, Singewald N. The role of substance P in stress and anxiety responses.
Amino Acids 2006; 31: 251–272.
86 Yan TC, Hunt SP, Stanford SC. Behavioural and neurochemical abnormalities in
mice lacking functional tachykinin-1 (NK1) receptors: A model of attention deficit
hyperactivity disorder. Neuropharmacology 2009; 57: 627–635.
87 Porter AJ, Pillidge K, Tsai YC, Dudley JA, Hunt SP, Peirson SN et al. A lack of
functional NK1 receptors explains most, but not all, abnormal behaviours of
NK1R− /− mice 1. Genes, Brain Behav 2015; 14: 189–199.
88 Pillidge K, Heal DJ, Stanford SC. The NK1R− /− mouse phenotype suggests that
small body size, with a sex- and diet-dependent excess in body mass and fat, are
physical biomarkers for a human endophenotype with vulnerability to attention
deficit hyperactivity disorder. J Psychopharmacol 2016; 30: 848–855.
89 Dando TM, Perry CM. Aprepitant: a review of its use in the prevention of
chemotherapy-induced nausea and vomiting. Drugs 2004; 64: 777–794.
90 Ebner K, Sartori SB, Singewald N. Tachykinin receptors as therapeutic targets in
stress-related disorders. Curr Pharm Des 2009; 15: 1647–1674.
91 Machado-Vieira R, Zarate CA. Proof of concept trials in bipolar disorder and major
depressive disorder: a translational perspective in the search for improved
treatments. Depress Anxiety 2011; 28: 267–281.
92 Olive MF. Neurokinin-1 (NK1) receptor antagonists as possible therapeutics
for psychostimulant use disorders. CNS Neurol Disord Drug Targets 2015; 14:
700–706.
93 Murtra P, Sheasby AM, Hunt SP, De Felipe C. Rewarding effects of opiates are
absent in mice lacking the receptor for substance P. Nature 2000; 405: 180–183.
94 Frank GKW. Altered brain reward circuits in eating disorders: chicken or egg? Curr
Psychiatry Rep 2013; 15: 396.
95 Palamiuc L, Noble T, Witham E, Ratanpal H, Vaughan M, Srinivasan S.
A tachykinin-like neuroendocrine signalling axis couples central serotonin action
and nutrient sensing with peripheral lipid metabolism. Nat Commun 2017; 8:
14237.
96 Sergeyev V, Hökfelt T, Hurd Y. Serotonin and substance P co-exist in dorsal raphe
neurons of the human brain. Neuroreport 1999; 10: 3967–3970.
97 Walker PD, Riley LA, Hart RP, Jonakait GM. Serotonin regulation of tachykinin
biosynthesis in the rat neostriatum. Brain Res 1991; 546: 33–39.
98 Froger N, Gardier AM, Moratalla R, Alberti I, Lena I, Boni C et al.
5-hydroxytryptamine (5-HT)1A autoreceptor adaptive changes in substance P
(neurokinin 1) receptor knock-out mice mimic antidepressant-induced desensi-
tization. J Neurosci 2001; 21: 8188–8197.
This work is licensed under a Creative Commons Attribution 4.0
International License. The images or other third party material in this
article are included in the article’s Creative Commons license, unless indicated
otherwise in the credit line; if the material is not included under the Creative Commons
license, users will need to obtain permission from the license holder to reproduce the
material. To view a copy of this license, visit http://creativecommons.org/licenses/
by/4.0/
© The Author(s) 2017
Supplementary Information accompanies the paper on the Translational Psychiatry website (http://www.nature.com/tp)
Modeling anorexia nervosa using iPSCs
PD Negraes et al
10
Translational Psychiatry (2017), 1 – 10
